Materialise Q3 2026 Revenue Reaches €67.67 Million as Medical Grows 9.7%
Materialise reported Q3 2026 revenue of €67.67 million, up 2.1%, with Medical revenue rising 9.7% while net profit declined to €1.38 million.
Materialise reported Q3 2026 revenue of €67.67 million, up 2.1%; excluding prior-year revenue from divested businesses, growth was 4.9%. Medical rose 9.7% to €36.54 million, Software fell about 4.1% to €9.86 million, and Manufacturing reported €21.27 million, down on a reported basis but up 1.5% after divestiture adjustments.
Adjusted EBITDA declined to €8.05 million from €8.43 million, while net profit fell to €1.38 million from €1.85 million. The company maintained 2026 guidance of €273–283 million in revenue and €12–14 million in adjusted EBIT. Reported results and company guidance are distinguished from independent business assessment.
Key facts
- Q3 revenue: €67.67 million (up 2.1%)
- Medical revenue: €36.54 million (up 9.7%)
- Net profit: €1.38 million
- Full-year revenue guidance: €273–283 million
Context
Personalized medical applications remained the largest growth driver, while weaker software revenue and higher R&D spending weighed on profitability.
